Incyte Corporation (INCY) 90.21 $INCY
ARIAD's (ARIA) Stock Up on Q2 Earnings & Revenue Beat
Arpita Dutt - Zacks Investment Research - Fri Jul 29, 8:23AM CDT
ARIAD (ARIA) swung to earnings in the second quarter while Iclusig sales continued to grow.
ZTS: 50.47 (+0.41), INCY: 90.21 (+2.09), ARIA: 9.51 (+0.04), NKTR: 17.29 (+1.19)
ARIAD (ARIA) to Report Q2 Earnings: Will the Stock Surprise?
Arpita Dutt - Zacks Investment Research - Tue Jul 26, 5:58AM CDT
Focus will remain on the performance of ARIAD's (ARIA) leukemia drug, Iclusig.
BMRN: 99.42 (+1.22), INCY: 90.21 (+2.09), AMGN: 172.03 (+0.75), ARIA: 9.51 (+0.04)
Updated Data for Epacadostat, Incyte's Selective IDO1 Inhibitor, Accepted for Presentation at the ESMO Annual Congress 2016
BusinessWire - Tue Jul 19, 6:35AM CDT
Incyte Corporation (Nasdaq:INCY) announces that updated data from the Phase 1 portion of the ECHO-202/KEYNOTE-037 trial has been accepted for a poster discussion at the European Society for Medical Oncology (ESMO) Annual Congress 2016, taking place in Copenhagen, Denmark from October 7-11, 2016. The ECHO-202 study (NCT02178722) is evaluating the safety and efficacy of epacadostat, Incyte's selective IDO1 inhibitor, in combination with Keytruda(R) (pembrolizumab)*, Merck's anti-PD-1 therapy.
INCY: 90.21 (+2.09), MRK: 58.66 (+0.23)
Incyte to Report Second Quarter Financial Results
BusinessWire - Thu Jul 14, 7:00AM CDT
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its second quarter 2016 financial results conference call and webcast for 10:00 a.m. ET on Tuesday, August 9, 2016.
INCY: 90.21 (+2.09)
Incyte Reports Epacadostat Combination Study Initiation
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 9:59AM CDT
Incyte (INCY) reported that the first patient has been treated in a phase III epacadostat combination study for advanced or metastatic melanoma.
ANIP: 60.60 (+0.99), INCY: 90.21 (+2.09), MRK: 58.66 (+0.23), BMY: 74.81 (+0.15)
FDA Grants Breakthrough Therapy Designation for Incyte's Ruxolitinib (Jakafi(R)) in Acute Graft-Versus-Host Disease (GVHD)
BusinessWire - Thu Jun 23, 6:30AM CDT
Incyte Corporation (Nasdaq: INCY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for ruxolitinib (Jakafi(R)) for the treatment of patients with acute graft-versus-host disease (GVHD). There are currently no approved treatments for patients with acute GVHD.
INCY: 90.21 (+2.09)
After Yesterday's Decline of 1.91%, Incyte Offers Investors Better Value
Comtex SmarTrend(R) - Tue Jun 21, 3:17PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $76.79 to a high of $79.40. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $76.92 on volume of 540,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
INCY: 90.21 (+2.09)
Incyte Falls 1.91% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jun 21, 3:16PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $76.79 to a high of $79.40. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $76.92 on volume of 540,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
INCY: 90.21 (+2.09)
Incyte's Jakafi Positive in Phase III for Polycythemia Study
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 8:15AM CDT
Incyte (INCY) announced new 28-week data from the phase III RESPONSE-2 study on Jakafi for the treatment of polycythemia vera.
INCY: 90.21 (+2.09), ABBV: 66.23 (+1.51), LLY: 82.89 (-0.04), BMY: 74.81 (+0.15)
New Phase 3 Data Show Jakafi(R) (ruxolitinib) is Superior to Best Available Therapy in Patients with Polycythemia Vera (PV)
BusinessWire - Fri Jun 10, 1:35AM CDT
--RESPONSE-2 data complements previous findings from RESPONSE, reinforcing Jakafi is effective in PV patients with or without an enlarged spleen
INCY: 90.21 (+2.09)
Baricitinib significantly reduces joint damage progression in rheumatoid arthritis in patients who do not respond to conventional DMARDs
CNW Group - Thu Jun 09, 5:45AM CDT
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced that data from a pivotal long-term extension study, RA-BEYOND, was presented at the Annual European Congress of Rheumatology (EULAR 2016) in London. The findings demonstrate that baricitinib was superior to placebo at inhibiting progressive radiographic joint damage in patients with rheumatoid arthritis (RA).
INCY: 90.21 (+2.09), LLY: 82.89 (-0.04)
Patient-reported outcomes across phase 3 studies of baricitinib demonstrate statistically significant improvements in physical function and quality of life symptoms in patients with rheumatoid arthritis (RA)
CNW Group - Thu Jun 09, 5:45AM CDT
Pivotal trials show treatment with baricitinib resulted in significant improvements in pain, fatigue and ability to perform daily activities compared to methotrexate - the current standard of care - and adalimumab (Humira(®))*
INCY: 90.21 (+2.09), LLY: 82.89 (-0.04)
Incyte Reports Five-Year Data from Phase III Study on Jakafi
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 8:45AM CDT
Incyte (INCY) announced five-year data from a phase III study on Jakafi for the treatment of patients with intermediate-2 or high-risk myelofibrosis.
INCY: 90.21 (+2.09), LLY: 82.89 (-0.04), BMY: 74.81 (+0.15), NVS: 83.26 (+1.18)
Premarket Research Report Covering the Biotech Industry
ACCESSWIRE - Mon Jun 06, 8:15AM CDT
LONDON, UK / ACCESSWIRE / June 6, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the biotech industry. Companies recently under review include Incyte, Chimerix, Lexicon Pharma, and Synthetic Biologics. Register with us now for your free membership and see our complete reports on these equities at:
SYN: 1.75 (-0.03), CMRX: 3.99 (-0.03), LXRX: 16.32 (-0.14), INCY: 90.21 (+2.09)
Five-year Results from Phase 3 Study of Jakafi(R) (ruxolitinib) Show Sustained Overall Survival Benefit in Patients with Myelofibrosis (MF)
BusinessWire - Mon Jun 06, 6:35AM CDT
--- These five-year data support previously published findings for Jakafi
INCY: 90.21 (+2.09)
ARIAD Completes the Sale of Its European Operations and Out-License of European Rights to Iclusig(R)
BusinessWire - Thu Jun 02, 6:35AM CDT
--~ ARIAD Receives $140 Million Upfront Payment, $135 million to be Received in Potential Oncology Milestones, Tiered Royalty Payments of Between 32% and 50%
INCY: 90.21 (+2.09), ARIA: 9.51 (+0.04)
Incyte and Moffitt Cancer Center Establish Multi-Year Oncology Research Alliance
BusinessWire - Wed Jun 01, 6:35AM CDT
Incyte Corporation (Nasdaq: INCY) and Moffitt Cancer Center today announced that they have entered into a research support and collaboration agreement, whereby Incyte has agreed to provide funding to conduct three new Moffitt Cancer Center research programs over a period of three years. The research programs will be focused on specific blood cancers, including myeloproliferative neoplasms (MPNs), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL) and chronic myelomonocytic leukemia (CMML). The objective of this alliance is to develop an improved understanding of basic cancer biology in the areas of focus, and interrogate specific therapeutic hypotheses involving Incyte's proprietary small molecule therapeutics, both as single agents and in combination.
INCY: 90.21 (+2.09)
Incyte Set to Possibly Pullback After Yesterday's Rally of 1.34%
Comtex SmarTrend(R) - Tue May 31, 4:33PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $84.68 to a high of $86.20. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $85.68 on volume of 381,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INCY: 90.21 (+2.09)
ARIAD's (ARIA) Stock Up on Q2 Earnings & Revenue Beat
Arpita Dutt - Zacks Investment Research - Fri Jul 29, 8:23AM CDT
ARIAD (ARIA) swung to earnings in the second quarter while Iclusig sales continued to grow.
ZTS: 50.47 (+0.41), INCY: 90.21 (+2.09), ARIA: 9.51 (+0.04), NKTR: 17.29 (+1.19)
ARIAD (ARIA) to Report Q2 Earnings: Will the Stock Surprise?
Arpita Dutt - Zacks Investment Research - Tue Jul 26, 5:58AM CDT
Focus will remain on the performance of ARIAD's (ARIA) leukemia drug, Iclusig.
BMRN: 99.42 (+1.22), INCY: 90.21 (+2.09), AMGN: 172.03 (+0.75), ARIA: 9.51 (+0.04)
Updated Data for Epacadostat, Incyte's Selective IDO1 Inhibitor, Accepted for Presentation at the ESMO Annual Congress 2016
BusinessWire - Tue Jul 19, 6:35AM CDT
Incyte Corporation (Nasdaq:INCY) announces that updated data from the Phase 1 portion of the ECHO-202/KEYNOTE-037 trial has been accepted for a poster discussion at the European Society for Medical Oncology (ESMO) Annual Congress 2016, taking place in Copenhagen, Denmark from October 7-11, 2016. The ECHO-202 study (NCT02178722) is evaluating the safety and efficacy of epacadostat, Incyte's selective IDO1 inhibitor, in combination with Keytruda(R) (pembrolizumab)*, Merck's anti-PD-1 therapy.
INCY: 90.21 (+2.09), MRK: 58.66 (+0.23)
Incyte to Report Second Quarter Financial Results
BusinessWire - Thu Jul 14, 7:00AM CDT
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its second quarter 2016 financial results conference call and webcast for 10:00 a.m. ET on Tuesday, August 9, 2016.
INCY: 90.21 (+2.09)
Incyte Reports Epacadostat Combination Study Initiation
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 9:59AM CDT
Incyte (INCY) reported that the first patient has been treated in a phase III epacadostat combination study for advanced or metastatic melanoma.
ANIP: 60.60 (+0.99), INCY: 90.21 (+2.09), MRK: 58.66 (+0.23), BMY: 74.81 (+0.15)
FDA Grants Breakthrough Therapy Designation for Incyte's Ruxolitinib (Jakafi(R)) in Acute Graft-Versus-Host Disease (GVHD)
BusinessWire - Thu Jun 23, 6:30AM CDT
Incyte Corporation (Nasdaq: INCY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for ruxolitinib (Jakafi(R)) for the treatment of patients with acute graft-versus-host disease (GVHD). There are currently no approved treatments for patients with acute GVHD.
INCY: 90.21 (+2.09)
After Yesterday's Decline of 1.91%, Incyte Offers Investors Better Value
Comtex SmarTrend(R) - Tue Jun 21, 3:17PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $76.79 to a high of $79.40. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $76.92 on volume of 540,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
INCY: 90.21 (+2.09)
Incyte Falls 1.91% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jun 21, 3:16PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $76.79 to a high of $79.40. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $76.92 on volume of 540,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
INCY: 90.21 (+2.09)
Incyte's Jakafi Positive in Phase III for Polycythemia Study
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 8:15AM CDT
Incyte (INCY) announced new 28-week data from the phase III RESPONSE-2 study on Jakafi for the treatment of polycythemia vera.
INCY: 90.21 (+2.09), ABBV: 66.23 (+1.51), LLY: 82.89 (-0.04), BMY: 74.81 (+0.15)
New Phase 3 Data Show Jakafi(R) (ruxolitinib) is Superior to Best Available Therapy in Patients with Polycythemia Vera (PV)
BusinessWire - Fri Jun 10, 1:35AM CDT
--RESPONSE-2 data complements previous findings from RESPONSE, reinforcing Jakafi is effective in PV patients with or without an enlarged spleen
INCY: 90.21 (+2.09)
Baricitinib significantly reduces joint damage progression in rheumatoid arthritis in patients who do not respond to conventional DMARDs
CNW Group - Thu Jun 09, 5:45AM CDT
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced that data from a pivotal long-term extension study, RA-BEYOND, was presented at the Annual European Congress of Rheumatology (EULAR 2016) in London. The findings demonstrate that baricitinib was superior to placebo at inhibiting progressive radiographic joint damage in patients with rheumatoid arthritis (RA).
INCY: 90.21 (+2.09), LLY: 82.89 (-0.04)
Patient-reported outcomes across phase 3 studies of baricitinib demonstrate statistically significant improvements in physical function and quality of life symptoms in patients with rheumatoid arthritis (RA)
CNW Group - Thu Jun 09, 5:45AM CDT
Pivotal trials show treatment with baricitinib resulted in significant improvements in pain, fatigue and ability to perform daily activities compared to methotrexate - the current standard of care - and adalimumab (Humira(®))*
INCY: 90.21 (+2.09), LLY: 82.89 (-0.04)
Incyte Reports Five-Year Data from Phase III Study on Jakafi
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 8:45AM CDT
Incyte (INCY) announced five-year data from a phase III study on Jakafi for the treatment of patients with intermediate-2 or high-risk myelofibrosis.
INCY: 90.21 (+2.09), LLY: 82.89 (-0.04), BMY: 74.81 (+0.15), NVS: 83.26 (+1.18)
Premarket Research Report Covering the Biotech Industry
ACCESSWIRE - Mon Jun 06, 8:15AM CDT
LONDON, UK / ACCESSWIRE / June 6, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the biotech industry. Companies recently under review include Incyte, Chimerix, Lexicon Pharma, and Synthetic Biologics. Register with us now for your free membership and see our complete reports on these equities at:
SYN: 1.75 (-0.03), CMRX: 3.99 (-0.03), LXRX: 16.32 (-0.14), INCY: 90.21 (+2.09)
Five-year Results from Phase 3 Study of Jakafi(R) (ruxolitinib) Show Sustained Overall Survival Benefit in Patients with Myelofibrosis (MF)
BusinessWire - Mon Jun 06, 6:35AM CDT
--- These five-year data support previously published findings for Jakafi
INCY: 90.21 (+2.09)
ARIAD Completes the Sale of Its European Operations and Out-License of European Rights to Iclusig(R)
BusinessWire - Thu Jun 02, 6:35AM CDT
--~ ARIAD Receives $140 Million Upfront Payment, $135 million to be Received in Potential Oncology Milestones, Tiered Royalty Payments of Between 32% and 50%
INCY: 90.21 (+2.09), ARIA: 9.51 (+0.04)
Incyte and Moffitt Cancer Center Establish Multi-Year Oncology Research Alliance
BusinessWire - Wed Jun 01, 6:35AM CDT
Incyte Corporation (Nasdaq: INCY) and Moffitt Cancer Center today announced that they have entered into a research support and collaboration agreement, whereby Incyte has agreed to provide funding to conduct three new Moffitt Cancer Center research programs over a period of three years. The research programs will be focused on specific blood cancers, including myeloproliferative neoplasms (MPNs), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL) and chronic myelomonocytic leukemia (CMML). The objective of this alliance is to develop an improved understanding of basic cancer biology in the areas of focus, and interrogate specific therapeutic hypotheses involving Incyte's proprietary small molecule therapeutics, both as single agents and in combination.
INCY: 90.21 (+2.09)
Incyte Set to Possibly Pullback After Yesterday's Rally of 1.34%
Comtex SmarTrend(R) - Tue May 31, 4:33PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $84.68 to a high of $86.20. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $85.68 on volume of 381,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INCY: 90.21 (+2.09)
